#Data card
Short data-led pieces; one chart, one takeaway.
No articles with this tag yet.
Browse other coverage
Latest from the blog
GLP-1s and shoulder replacement safety
A claims-database study found more 90-day readmissions among non-diabetic GLP-1 users after shoulder replacement, but it cannot establish cause.
Iran's GLP-1 Cost-Effectiveness Model
An Iranian 68-week model found semaglutide cost-effective at its threshold, while tirzepatide offered more benefit at a higher estimated cost.
Semaglutide and Handgrip Strength
A new systematic review found very low-certainty evidence on handgrip strength after semaglutide, not proof of strength preservation or loss.
How Oral Semaglutide Enhancers Differ
A preclinical comparison of SNAC, DDM and LLC found distinct intestinal transport and barrier-response patterns for semaglutide.
TAB trial: tirzepatide plus buprenorphine
The recruiting TAB trial will test tirzepatide added to buprenorphine for opioid use disorder, but its design paper reports no outcomes.
Tirzepatide and Lithium: A New Case Report
A newly indexed case report links tirzepatide and lithium toxicity, but its accessible record contains no clinical details or evidence of causation.